Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43–66.
Fong Y, Blumgart L. Hepatic colorectal metastases: current status of surgical therapy. Oncology 1998; 12: 1489–98.
Fong Y, Cohen A, Fortner J, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997; 15: 938–46.
Fong Y, Salo J. Surgical therapy of hepatic colorectal metastases. Semin Oncol. 1999; 26: 514–23.
Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet. Oncol. 2001; 2: 418–28.
Bilchik AJ. Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update. Surg Oncol Clin N Am. 2003; 12: 193–210.
Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001; 19: 2687–95.
Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987; 206: 685–93.
Grosso M, Scarrone A, Pedrazzini F, et al. Intra-arterial hepatic chemotherapy: management of liver tumors by percutaneous port-a-cath positioning. J Exp Clin Cancer Res. 2003; 22: 171–5.
Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987; 107: 459–65.
Kemeny N, Conti J, Cohen A, et al. Phase II study of hepatic fluorouridine, leucovorin and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994; 12: 2288–95.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastasis from colorectal cancer. N Engl J Med. 1999; 341: 2039–48.
Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases. Ann Surg. 1998; 228: 756–62.
Chung KY, Kemeny N. Regional and systemic chemotherapy for primary hepatobiliary cancer and for colorectal cancer metastatic to the liver. Semin Radiat Oncol. 2005; 15: 284–98.
Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005; 23: 4888–96.
Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomized trial. J Clin Oncol. 1992; 10: 1112–8.
Kemeny N. Current approaches for liver-only metastases in colorectal cancer. Commun Oncol. 2006; 3: 26–35.
Franklin ME Jr, Gonzalez J Jr. Laparoscopic placement of hepatic artery catheter for regional chemotherapy infusion: technique, benefits, and complications. Surg Laparosc Endosc Percutan Tech. 2002; 12: 398–407.
Franklin M, Trevino J, Hernandez-Oaknin H, et al. Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease? Surg Endosc. 2006; 20: 554–8.
Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989; 7: 1646–54.
Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992; 69: 327–34.
Martin JK, O’Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg. 1990; 125: 1022–27.
Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet. 1994; 344: 1255–60.
Lorenz M, Muller HH. Randomized, multi-center trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000; 18: 243–54.
Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg. 2003; 90: 1391–7.
Rougier P, Van Cutsem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 1407–13.
Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Onocol. 1993; 11: 909–13.
Cunningham D, Pyrhonen S, James R, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413–8.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337–45.
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25: 1539–44.
Kemeny MM, Adak S, Gray B, et al. Combined modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002; 20: 1499–1505.
Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990; 8: 1885–93.
Kemeny N, Niedzwiecki D, Hollis D, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer; a randomized trial of efficacy, quality of life, and molecular markers. J Clin Oncol. 2006; 24: 1395–403.
Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgery and radiofrequency ablation for unresectable hepatic malignancies: a proposed algorithm. Arch Surg. 2000; 135: 657–62.
Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 2000; 230: 1–8.
Scaife CL, Curley SA, Izzo F, et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol. 2003; 10: 332–3.
Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol. 2000; 7: 593–600.
Weaver M, Ashton J, Zemel R. Treatment of colorectal liver metastases by cryotherapy. Semin Surg Oncol. 1998; 14: 163–70.
Yan TD, Padang R, Morris DL. Long term results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: long term survival can be achieved in patients with multiple bilateral liver metastases. J Am Coll Surg. 2006; 202: 100–11.
Bilchik AJ, Wood TF, Chawla SP, et al. Systemic irinotecan or floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clin Colorectal Cancer. 2001; 1: 36–42.
Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal carcinoma. J Surg Oncol. 2005; 91: 97–101.
Litvak D, Wood T, Tsioulias G, Chung M, et al. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol. 2002; 9: 148–55.
Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005; 23: 4881–7.
Lygidakis NJ, Bhagat AD, Vrachnos P, et al. Challenges in everyday surgical practice: synchronous bilobar hepatic colorectal metastases—newer multimodality approach. Hepatogastroenterology. 2007; 54: 1020–4.
Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005; 23: 9073–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London
About this chapter
Cite this chapter
Telian, S.H., Wright, B.E., Bilchik, A.J. (2009). Locoregional Chemotherapy for Hepatic Metastasis of Colorectal Cancer. In: Vauthey, JN., Hoff, P., Audisio, R., Poston, G. (eds) Liver Metastases. Springer, London. https://doi.org/10.1007/978-1-84628-947-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-84628-947-7_6
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84628-946-0
Online ISBN: 978-1-84628-947-7
eBook Packages: MedicineMedicine (R0)